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Background: A large proportion of patients with acute myeloid leukemia (AML) are not fit for intensive and
potentially curative therapy due to advanced age or comorbidity. Previous studies have demonstrated that a subset
of these patients can benefit from disease-stabilizing therapy based on all-trans retinoic acid (ATRA) and valproic
acid. Even though complete hematological remission is only achieved for exceptional patients, a relatively large
subset of patients respond to this treatment with stabilization of normal peripheral blood cell counts.
Methods: In this clinical study we investigated the efficiency and safety of combining (i) continuous administration
of valproic acid with (ii) intermittent oral ATRA treatment (21.5 mg/m2 twice daily) for 14 days and low-dose
cytarabine (10 mg/m2 daily) for 10 days administered subcutaneously. If cytarabine could not control
hyperleukocytosis it was replaced by hydroxyurea or 6-mercaptopurin to keep the peripheral blood blast count
below 50 × 109/L.
Results: The study included 36 AML patients (median age 77 years, range 48 to 90 years) unfit for conventional
intensive chemotherapy; 11 patients responded to the treatment according to the myelodysplastic syndrome (MDS)
response criteria and two of these responders achieved complete hematological remission. The most common
response to treatment was increased and stabilized platelet counts. The responder patients had a median survival
of 171 days (range 102 to > 574 days) and they could spend most of this time outside hospital, whereas the
nonresponders had a median survival of 33 days (range 8 to 149 days). The valproic acid serum levels did not differ
between responder and nonresponder patients and the treatment was associated with a decrease in the level of
circulating regulatory T cells.
Conclusion: Treatment with continuous valproic acid and intermittent ATRA plus low-dose cytarabine has a low
frequency of side effects and complete hematological remission is seen for a small minority of patients. However,
disease stabilization is seen for a subset of AML patients unfit for conventional intensive chemotherapy.Background
Acute myeloid leukemia (AML) is an aggressive malig-
nancy that can only be cured by intensive chemotherapy
and, if necessary, in combination with autologous or allo-
geneic stem cell transplantation [1]. However, due to an
unacceptably high risk of early treatment-related mor-
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reproduction in any medium, provided the orfor elderly patients and for patients with associated co-
morbidity [2,3]. These patients are therefore treated with
either supportive therapy alone or in combination with
AML-directed low-toxicity chemotherapy in an attempt
to stabilize the disease [4,5].
Several previous studies have indicated that histone
deacetylase (HDAC) inhibitors can induce disease con-
trol in AML [6,7]. Valproic acid is the HDAC inhibitor
used in most of these studies, but butyric acid and
depsipeptide seem to have similar effects [7]. Taken to-
gether, these previous studies demonstrate that HDAC
inhibitors, usually administered in combination with all-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with improvement of normal peripheral blood cell
counts for a subset of AML patients. However, based on
the overall results from several studies including more
than 200 patients, complete hematological remissions
seem very uncommon [8-15]. The duration of these re-
sponses varies, but they may last for more than a year.
However, none of these previous studies included the
systematic use of low-toxicity chemotherapy, even
though such treatment was allowed in some studies to
control hyperleukocytosis [9,10,12-14]. Another recent
study also showed an effect of the combination of val-
proic acid and low-dose cytarabine, but these patients
did not receive ATRA and the cytarabine dose was
higher and given more frequent [16] than in our present
study where we combined continuous valproic acid ther-
apy with intermittent ATRA treatment and low-dose
cytarabine. Our study is a single-institution study includ-
ing a consecutive group of unselected and mainly older
AML patients. Our results demonstrate that the treat-
ment was well-tolerated and disease stabilization with
improvement of normal peripheral blood cell counts was
observed for a subset of patients.
Methods
Patients included in the study
We included 36 consecutive AML patients from our de-
partment from February 2008 to February 2012 (median
age 77 years with variation range 48 to 90 years; 22 fe-
males and 14 males). All patients had non-M3-AML di-
agnosed in accordance with established WHO-criteria.
All patients were included after written informed con-
sent and the study was performed in accordance with
the Helsinki declaration and approved by the local ethics
committee (REK Vest 231.06). Collection of the clinical
data was approved by the official Norwegian Social Sci-
ence Data Service Authority (NSD17293) and the study
was registered in public databases (ClinicalTrials.gov
number NCT00995332 and EudraCT number 2007-2007-
001995-36).
This was a phase II study, planned to include patients
during a four year period and inclusion of at least 30 pa-
tients was expected. The approved protocol stated that
inclusion should be continued and completed only if at
least 2 of the first 10 patients responded to the treat-
ment. Among the first 10 patients, we had one complete
remission and 1 patient with stable disease of more than
two month’s duration according to the myelodysplastic
syndrome (MDS) response criteria. Our hypothesis was
that the combination of a cytotoxic drug together with
valproic acid + ATRA was feasible as an outpatient
treatment for older and unfit AML patients. Our objec-
tives were therefore to evaluate the effects of this treat-
ment on (i) overall survival, (ii) the general clinicalstatus and the disease status, and (iii) normal peripheral
blood cell counts, including reticulated platelets and im-
munocompetent cells. The patients followed our regular
control program; the Ethics Committee did not allow
additional bone marrow aspirations, and for this reason
extra bone marrow sampling during treatment was only
done to confirm complete remission if the peripheral
blood cell counts fulfilled the remission criteria.
Control patients only receiving supportive treatment
Our results were compared with a group of 14 patients
who received only supportive therapy but no AML-
directed treatment. These patients represent all AML
patients not receiving intensive chemotherapy from our
institution that were registered in the Norwegian AML
Registry during the years 2000 to August 2004 (median
age 78.5 years with range 70 to 89 years; seven men and
seven women). They all had a recent diagnosis of AML,
that is, no patients with leukemic relapse were included
in this group. They were all treated according to the
same institutional general guidelines as the patients in-
cluded in the present study, that is, (i) they did not
receive any kind of AML-directed chemotherapy; (ii)
growth factor treatment was not used; (iii) they were
followed at our outpatient department at regular inter-
vals in a similar way to the patients included in the
study, and (iv) all routines for antibiotic therapy as well
as platelet and erythrocyte transfusions were also similar
to the study patients.
Treatment of the patients
On day 1, the patients received an initial loading dose of
valproic acid 5 mg/ml during 30 minutes and thereafter
a continuous intravenous infusion (28 mg/kg) for the
next 24 hours before oral treatment was started with
300 mg twice daily. This treatment was then continued
indefinitely and the dose was adjusted to the highest tol-
erated dose not exceeding the upper limit of the thera-
peutic serum level of 300 to 600 μmol/L. Oral treatment
with ATRA (21.5 mg/m2 twice daily) was given for 14
days from day 8 to 22 and repeated every 12th week.
Cytarabine (10 mg/m2 daily) was given subcutaneously
on days 15 to 24 and was also repeated every 12th week.
For patients with rapidly increasing peripheral blood
blast counts exceeding or expected to exceed 50 × 109/L,
all three drugs were started on day 1, but the doses and
duration of treatment were similar to those described
above.
Response criteria
The international working group in AML [17] defined
complete remission (CR) of AML as (i) less than 5%
blasts in the bone marrow, no Auer rods and no persist-
ence of extra-medullary disease, and (ii) neutrophil
Fredly et al. Clinical Epigenetics 2013, 5:13 Page 3 of 15
http://www.clinicalepigeneticsjournal.com/content/5/1/13counts above 1.0 × 109/L, platelet levels above 100 × 109/L
and transfusion independence. There is no requirement in
terms of duration of this response. The MDS response cri-
teria [18,19] generally require a duration of eight weeks
for the response. The requirements for CR in MDS are (i)
less than 5% blasts in the bone marrow and no dysplasia,
(ii) hemoglobin level > 11 g/100 ml, neutrophil counts
> 1.5 × 109/L, platelet counts > 100 × 109/L and (iii) no
circulating blasts. These MDS criteria define stable disease
as no evidence of progression for at least eight weeks.
Estimation of reticulated platelets, Th17 and Treg cells in
peripheral blood
Estimating the fraction of reticulated platelets in periph-
eral blood was performed as described in detail previ-
ously [20]. Frequencies of Treg and Th17 cells were also
determined as described in detail previously [21].
Statistical analyses
For comparisons between groups, we used the Mann–
Whitney U-test; for paired observations the Wilcoxon’s
signed rank test was used; and for analyses of catego-
rized data we used the Pearson’s chi-square test. Differ-
ences were generally regarded as statistically significant
when P-values were < 0.05.
Results
Patients and treatment
We included 36 patients; their clinical and biological
characteristics are summarized in Table 1. During this
period, five additional AML patients unfit for intensive
chemotherapy were admitted to our hospital but were
not included in the study; these patients were (i) one pa-
tient with relapsed AML who did not accept inclusion;Table 1 The frequencies of relapsed and secondary acute
myeloid leukemia (AML), signs of differentiation (FAB
subclasses, CD34 expression) and genetic abnormalities
among unselected AML patients unfit for intensive therapy
FAB classification
M0/M1 0.41
M2 0.23
M4/M5 0.36
Expression of CD34 (> 20% positive cells) 0.70
Cytogenetic abnormalities
Normal 0.50
Good 0.00
Intermediate 0.20
Adverse 0.30
Flt3- internal tandem duplication 0.40
NPM-1 mutation 0.35(ii) two patients could not give informed consent; (iii)
adequate follow-up was not possible for one patient; and
(iv) one patient had already started treatment with hy-
droxyurea and could not be included in the protocol.
Eleven patients had AML secondary to MDS; four of
these had received treatment with 5-azacitidine before
leukemic transformation and one of them had received
intensive AML induction chemotherapy without rea-
ching hematological remission before he was included in
the present study. One patient had previous myelofibro-
sis and three patients previous polycythemia vera; two of
these polycythemia vera patients had received hydroxy-
urea treatment. Two patients had previously received
treatment with cytotoxic drugs due to breast cancer.
Seven patients had AML relapse after previous treat-
ment - intensive chemotherapy (five patients), autolo-
gous (one patient) or allogeneic (one patient) stem cell
transplantation. One of these patients had a relapse during
ongoing consolidation therapy and three other patients
had their relapse five months or less after consolidation
therapy was completed.
Due to rapidly progressive disease with hyperleu-
kocytosis, nine patients started with all three drugs from
day 1. Furthermore, two patients died within two days
after the start of therapy and were not included in our
final analyses; three additional patients died within 14
days. The total mortality at two weeks was thus five
patients and the total at four weeks was 12 out of 36 pa-
tients; most of these patients died from disease progres-
sion. ATRA treatment was started in all 36 patients (day
1, 9 patients; day 8, 27 patients) and completed for 24 of
them, cytarabine treatment was started for 35 patients
(day 1, 9 patients; day 15, 26 patients) and completed for
17 patients. The median ATRA and cytarabine doses for
patients receiving reduced doses were 40% and 60%, re-
spectively, of the planned dose. For these patients the
treatment was reduced or ended due to progressive dis-
ease and/or increasing and severe thrombocytopenia.
Thus, only 15 patients completed 14 days with ATRA
and 10 days with cytarabine therapy together with con-
tinuous valproic acid treatment, and 14 of these patients
received this therapy as a sequential treatment during
the initial 24 days.
Evaluation of response to treatment according to
conventional AML criteria - 2 out of 36 patients achieved
complete hematological remission
There is no general agreement with regard to which re-
sponse criteria should be used for AML patients receiv-
ing low-toxicity or disease-stabilizing treatment [15],
and we therefore evaluated our patients both with regard
to the conventional criteria for patients receiving inten-
sive AML chemotherapy [17] and also according to the
MDS criteria [19]. Two out of 36 patients achieved CR
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and one of these patients had an adverse prognosis
according to conventional risk stratification with AML
secondary to MDS.
Evaluation of response to treatment according to MDS
criteria - two patients showed complete remission and
nine additional patients showed hematological
improvement of normal peripheral blood cell counts
lasting for at least eight weeks
Patients came to regular reviews that included clinical
examination and blood sample analyses. Bone marrow
aspiration was performed if peripheral blood samples
showed an improvement that fulfilled the criteria for CR.
According to the MDS response criteria [19], the re-
sponses had to last for a minimum of two months, that is,
there should be no evidence of progression for at least
two months. Based on the peripheral blood cell counts,
nine of our evaluable patients fulfilled the criteria for
hematological improvement based on normal peripheral
blood cell counts (Table 3) in addition to the two com-
plete remission patients (Table 2); that is, they showed an
increase from pretreatment normal peripheral blood cell
counts fulfilling the criteria for hematological improve-
ment, and the MDS criteria for relapse or progression
after hematological improvement were fulfilled after more
than eight weeks. The nine patients with such disease
stabilization were five females and four males with a
median age of 77 years (range 66 to 85 years); the 23 non-
responders were 16 females and seven males with a
median age of 77 years (range 48 to 90 years).Table 2 Responses to treatment with valproic acid+all-trans r
the results for the two acute myeloid leukemia (AML) patient
Patient characteristics and
treatment responses
Detailed description of disease cha
CR1 Risk factor: AML secondary to previou
Female, 83 years old Status at diagnosis: performance status 1
Treatment duration: 9 months Valproic acid level: average level first 4
Response duration: 4 monthsSurvival:
296 days
Peripheral blood cell counts: (i) platel
neutrophils > 1.5 × 109/L for 4 mont
11 g/dl for 4 months.
CR2a Risk factors: none, de novo AML.
Male, 71 years old Status at diagnosis: performance stat
pancytopenia with circulating blasts
Treatment duration: 7 months
Response duration: 2 months Valproic acid level: average level first 4
Survival: 383 days Peripheral blood cell counts: (i) > 100
> 11 g/100mL for 2.5 months with tr
Patient identity refers to response (CR complete remission) according to the conven
refers to the time receiving valproic acid, ATRA and low-dose cytarabine according
and the last review documenting a peripheral blood cell value above the indicated
aReceived later chemotherapy with hydroxyurea to control peripheral blood blast cThe peripheral blood values for the responders are
presented in Table 4; increased levels are usually seen
after one to two weeks [15] and the table therefore com-
pares the lowest value during the first 14 days of treat-
ment (and not the pretreatment values used for the
evaluation of hematological improvement) and the
highest value determined during treatment. Cell counts
remained relatively low during the first two weeks of
treatment and maximal responses were often reached
after several weeks. Platelet responses were most com-
mon. Minor neutrophil responses were less common,
and normal neutrophil counts during treatment were
only seen for three patients (SD7-9) who also had nor-
mal counts at the time of diagnosis. Transfusion inde-
pendence was only seen for three of the patients.
The 23 non-responders all had early disease progres-
sion during treatment; 19 of them had a survival shorter
than eight weeks and three of them died within two
weeks after the start of treatment. We also applied the
response criteria as described by Ryningen et al. [15]
who required a shorter response duration than two
months to classify patients as responders, but those pa-
tients classified as responders according to these criteria
corresponded to the group with remission/stable disease
according to the MDS criteria.
Twelve patients (median age 77 years, range 48 to 86
years) died less than four weeks after initiation of treat-
ment; nine of these patients had a poor performance sta-
tus (3 to 5) at initiation of treatment, whereas the last
three patients had a pretreatment performance status of
0 to 2 but showed chemoresistance with early progres-
sion and hyperleukocytosis/leukostasis.etinoic acid (ATRA)+low-dose cytarabine; a summary of
s achieving complete hematological remission (CR)
racteristics and the clinical course
s primary myelodysplastic syndrome (MDS).
, 35% blasts in bone marrow; pancytopenia with circulating blasts < 0.5 × 109/L.
weeks 353 μmol/L and during the whole treatment period 326 μmol/L.
et counts >100 × 109/L for 4 months and > 30 × 109/L for 7 months; (ii)
hs; and (iii) no erythrocyte transfusions for 10 months and values Hb >
us 3, > 20% blast in bone marrow judged from bone biopsy,
< 0.5 × 109/L.
weeks 419 μmol/L and during the whole treatment period 499 μmol/L.
× 109/L for 3 months; (ii) neutrophils > 1.5 × 109/L for 2 months; (iii) Hb
ansfusion independence.
tional AML criteria [17] and their consecutive number. Duration of treatment
to the protocol. The duration of responses refers to the time between the first
level.
ount.
Table 3 Responses to treatment with valproic acid+all-trans retinoic acid (ATRA)+low-dose cytarabine according to the
myelodysplastic syndrome (MDS) criteria for hematological improvement (increased cell counts for at least eight
weeks); a summary of the observations for nine acute myeloid leukemia (AML) patients fulfilling these criteria
(referred to as stable disease, SD)
Patient characteristics and
treatment responses
Detailed description of disease characteristics and the clinical course
SD1 - stable disease Risk factor: previous primary MDS.
Male, 83 years Status at diagnosis: performance status 0 to 2, 45% blasts in bone marrow; circulating blasts < 0.5 × 109/L.
Duration of treatment: 3 months Valproic acid level: 340 μmol/L.
Response duration: 2.5 months Peripheral blood cell counts: (i) platelet counts > 15 × 109/L for 2.5 months; (ii) neutrophils > 0.1 × 109/L for 3
months; and (iii) erythrocyte level > 8.5 × 109 for 2.5 months without transfusions.
Survival: 102 days
SD2 - stable diseasea Risk factor: previous primary MDS.
Female, 77 years Status at diagnosis: performance status 0 to 2, 25% blasts in bone marrow; circulating blasts < 0.5 × 109/L.
Duration of treatment: 10 months Valproic acid level: 324 μmol/L.
Response duration: 3.5 months Peripheral blood cell counts: (i) platelet counts > 25 for 7 months; (ii) neutrophils > 0.2 × 109 for 5 months;
and (iii) erythrocyte level > 8.5 × 109 for 3.5 months without transfusions.
Survival: 419 days
SD3- stable disease Risk factor: previous primary MDS.
Female, 85 years Status at diagnosis: performance status 0 to 2, 70% blasts in bone marrow; circulating blasts < 0.5 × 109/L
Duration of treatment: 5.5 months Valproic acid level: 442 μmol/L.
Response duration: 2 months Peripheral blood cell counts: (i) platelet counts > 18 × 109 for 2 months; (ii) neutrophils could mostly not be
reported; and (iii) erythrocyte level > 8.5 × 109 for 3 months with stable transfusion level
Survival: 171 days
SD4 – stable disease Risk factor: none
Male, 74 years Status at diagnosis: performance status 3 to 5, > 20% blasts in bone marrow; circulating blasts > 15 × 109/L
Duration of treatment: 2 months Valproic acid level: 70 μmol/L.
Response duration: 3 months Peripheral blood cell counts: (i) platelet counts > 50 × 109 for 3 months, > 100 for 1 month; (ii) neutrophils
could mostly not be reported; and (iii) erythrocyte level > 8.5 × 109 for 4 months with stable transfusion level.
Survival: 151 days
SD5 – stable diseasea Risk factor: previous primary MDS, incomplete response to 5-azacitidine for AML.
Male, 66 years
Duration of treatment: 7.5 months Status at diagnosis: performance status 0 to 2, > 15% blasts in bone marrow when included in the study;
circulating blasts < 0,5 × 109/L.
Response duration: 2 months Valproic acid level: 419 μmol/L.
Survival: 239 days Peripheral blood cell counts: (i) platelet counts > 10 × 109 for 2 months; (ii) neutrophils stable 0.1 × 109/L for
3 months; and (iii) erythrocyte level > 8.5 × 109 for 2 months without transfusions.
SD6 - stable disease Risk factor: none
Female, 78 years Status at diagnosis: performance status 0 to 2, > 20% blasts in bone marrow; circulating blasts < 0,5 × 109/L.
Duration of treatment: 4.5 months Valproic acid level: 476 μmol/L
Response duration: 2 months Peripheral blood cell counts: (i) platelet counts > 30 × 109/L for 2 months; (ii) neutrophils stable around 0.1 ×
109/L; and (iii) erythrocyte level > 8.5 × 109/L for 3 months with stable transfusion frequency.
Survival: 147 days
SD7 - stable diseasea Risk factor: previous primary MDS
Female, 72 years Duration of
treatment: 1 month
Status at diagnosis: performance status 0 to 2, > 30% blasts in bone marrow; circulating blasts > 30 × 109/L
Valproic acid level: 478 μmol/L.
Response duration: 3 months Peripheral blood cell counts: (i) platelet counts > 15 × 109 for 3 months with stable transfusion frequency; (ii)
neutrophils could not be reported; and (iii) erythrocyte level > 8.5 × 109 for 3 months with stable transfusion
frequency.Survival: 132 days
SD8- stable diseasea Risk factor: previous polycythemia vera, AML with del(5)
Male, 81 years Status at diagnosis: performance status 0 to 2, 25% blasts in bone marrow; circulating blasts > 20 × 109/L.
Duration of treatment: 4 months Valproic acid level: 404 μmol/L
Fredly et al. Clinical Epigenetics 2013, 5:13 Page 5 of 15
http://www.clinicalepigeneticsjournal.com/content/5/1/13
Table 3 Responses to treatment with valproic acid+all-trans retinoic acid (ATRA)+low-dose cytarabine according to the
myelodysplastic syndrome (MDS) criteria for hematological improvement (increased cell counts for at least eight
weeks); a summary of the observations for nine acute myeloid leukemia (AML) patients fulfilling these criteria
(referred to as stable disease, SD) (Continued)
Response duration: 2 months Peripheral blood cell counts: (i) Platelet counts > 30 × 109 for 3 months; (ii) neutrophils > 0.2 × 109 for 2
months; and (iii) erythrocyte level > 8.5 × 109 for 2 months with stable transfusion frequency.
Survival: > 574 days
SD9 – stable diseasea Risk factor: previous primary MDS.
Female, 77 years Status at diagnosis: performance status 0 to 2, 30 % blasts in bone marrow; circulating blasts > 25 × 109/L.
Duration of treatment: 3.5 months Valproic acid level: 467 μmol/L
Response duration: > 2 months Peripheral blood cell counts: (i) platelet counts > 25 × 109 for > 2 months; (ii) neutrophils could not be
reported; and (iii) erythrocyte level > 8.5 for 4 months with stable transfusion frequency.
Survival: > 141 days
Patient identity refers to the response (SD, stable disease) according to the MDS criteria for hematological improvement [19] and a consecutive numbering.
Duration of treatment refers to the time receiving valproic acid, ATRA and low-dose cytarabine according to the protocol. The valproic acid level is presented as
the average serum level during the four first weeks of treatment. The duration of responses refers to the time between the first and the last review documenting
a peripheral blood cell value above the indicated level.
aReceived later chemotherapy with hydroxyurea or 5-mercaptopurin to control the blood blast count.
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the use of other cytotoxic drugs instead of low-dose
cytarabine to control hyperleukocytosis
Low-dose cytarabine was included as part of the study
treatment, but despite this, nine patients developed
hyperleukocytosis that was treated with other cytore-
ductive drugs. Six of these patients were classified as ini-
tial responders (that is, stable disease) whereas three
were non-responders. Even though some of the respon-
ders (indicated in Tables 2 and 3) received this add-
itional treatment relatively early, they all lived for several
months after this change; this was true both for patient
SD7 (new treatment after one and a half months, lived
for additional three months), patient SD5 (two months/
five and a half months), patient SD9 (three and a half
months/three months), patient SD8 (four and a half
months/nineteen months), patient CR2 (seven months/
six months) and patient SD2 (eleven months/threeTable 4 Delayed increase in peripheral blood cell counts for a
during treatment with all-trans retinoic acid (ATRA), valproic
pretreatment/early treatment values versus maximal levels
Platelet Neutrophil
Patient Before or during the
first 14 days
Highest value during
treatment
Before or du
first 14 days
SD1 12 49 (90) 0.1
SD2 22 64 (273) 0.1
SD3 < 5 79 (55) 0.4
SD4 103 302 (51) 0.5
SD5 19 51 (136) < 0.1
SD6 55 81 (106) < 0.1
SD7 18 30 (15) 9.8
SD8 48 98 (40) 3.8
SD9 28 96 (141) 2.9
The values before treatment represent the lowest value during this time. The highe
and the parenthesis gives the day after start of treatment when this value was regimonths). It should be emphasized that the indication
for changing the cytotoxic treatment was increasing
leukocytosis which is not included in the criteria for
hematological improvement according to the MDS cri-
teria. Thus, some of our responders received another
cytoreductive therapy during their period of stabilization.
In the nonresponder patients the new drug was started
after less than four months (half, one and four months
respectively) and they all had an overall survival of less
than five months (one, two and five months respect-
ively). Hydroxyurea was tried first in all these patients
and for four patients, 6-mercaptopurin was also used
because hydroxyurea was judged to be ineffective. The
dosages of both these drugs were adjusted to the min-
imal dose to keep the peripheral blood blast counts
below 50 × 109/L.
The definition of stable disease according to the MDS
criteria requires no evidence of progression for eightcute myeloid leukemia (AML) patients with stable disease
acid and low-dose cytarabine; a comparison of
Erythrocyte
ring the Highest value during
treatment
Transfusion independent >
two months
0.7 (102) yes
0.8 (77) yes
0.4 (74) -
0.2 (126) -
0.3 (67) yes
0.2 (112) -
7.2 (27) -
8.2 (473) -
1.8 (49) -
st value represents the value registered after the first 14 days of treatment,
stered. The units for both platelet and neutrophil counts are × 109 /L.
Figure 1 The overall survival of acute myeloid leukemia (AML)
patients after treatment with all-trans retinoic acid (ATRA),
valproic acid and low-dose cytarabine. The figure presents a
comparison of responder and nonresponder patients according to
the MDS criteria [19]. The mean survival is indicated for each group.
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be regarded as progression, and thus only eight of our
nine patients (not patients SD7, see Table 3) with
hematological improvement fulfilled the MDS definition
of stable disease.
Valproic acid serum levels did not differ between
nonresponders and patients with stable disease
Valproic acid was used from day one and continued in-
definitely. The dose was adjusted according to side ef-
fects; the highest tolerated dose was given and if possible
the serum levels should then be within the therapeutic
serum level of 300 to 600 μmol/L. The median serum
level during the first four weeks of treatment did not
differ between patients with remission/stable disease
(median average level 404 μmol/L, variation range 70 to
478) and the nonresponders (median average level 351
μmol/L, range 100 to 545, Mann–Whitney U-test, P =
0.3202). The later valproic acid serum levels generally
corresponded to the levels reached during the initial four
weeks (data not shown).
Evaluation of treatment with regard to survival -
responder patients showed increased survival compared
to nonresponder patients and patients only receiving
supportive therapy
The 11 patients with complete remission and stable dis-
ease according to the MDS criteria are referred to as re-
sponders and the 23 others as nonresponders. The median
survival for all our patients was 46.5 days (range 8
to >574); for the responders the median survival was 171
days (range 102 to >574) whereas the nonresponders had
significantly shorter median survival of only 33 days (range
8 to 149) (Figure 1, Mann–Whitney U-test, P < 0.0001).
Even our patients with stable disease but without remis-
sion showed a relatively long survival (median 151, range
102 to >574), and this was also significantly longer than
for the nonresponders (Mann–Whitney U-test, P < 0.0001).
Furthermore, a group of 14 control patients with newly di-
agnosed AML and unfit for intensive chemotherapy had a
median survival of 75 days (range 1 to 215 days) and this
is also significantly shorter than the nine stable disease pa-
tients and the 11 responders (P = 0.0140 and P = 0.0037
respectively, Mann–Whitney U-test).
There were no significant differences with regard to
age, gender distribution, peripheral blood counts of leu-
kocytes/blasts, circulating platelet or hemoglobin levels,
de novo versus secondary leukemia, cytogenetic or mo-
lecular genetic (Flt3 or NPM1 mutations) abnormalities
between responders and nonresponders in our study
(data not shown). All patients had > 20% blasts in the
bone marrow at the time of first AML diagnosis, as re-
quired by the WHO criteria; at the time of inclusion,
three of the relapse patients had < 20% of blasts in the
Table 5 Days in hospital for acute myeloid leukemia
(AML) patients responding to treatment with valproic
acid, all-trans retinoic acid (ATRA) and low-dose
cytarabine
Patient Overall
survival
(days)
Days in hospital relative to the total number
of days:
From start of therapy
to death
For the last 28 days
before death
CR1 296 59/ 296 0
CR2 383 42/ 383 8
SD1 102 18/ 102 14
SD2 419 20/ 419 6
SD3 171 54/ 171 4
SD4 151 93/ 151 23
SD5 239 80/ 239 18
SD6 147 35/ 147 2
SD7 132 41/ 132 4
SD8 > 574 12/ > 574 Still alive and living at home
SD9 > 141 12/ > 141 Still alive and living at home
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diagnosis the median blast count was 50% (range 20 to
95%) and the counts did not differ between responders
and nonresponders.
The pretreatment clinical status was evaluated by the
WHO performance status and by the hematopoietic cell
transplantation comorbidity index (HCT-CI) [22] that
has been shown to predict early death in AML patients
older than 60 years of age and receiving intensive induc-
tion treatment [23]. At the start of treatment, 21 patients
had a WHO performance-status between 0 (asymp-
tomatic) and 2 (symptomatic but less than 50% in
bed during the day) [24], whereas 15 patients had
performance-status equal to or higher than 3 (more than
50% in bed during the day). We compared the perform-
ance status for nonresponders and responders, and
found no significant difference between the two groups
(P = 0.1193, Mann–Whitney U-test). Furthermore, 17
patients had a HCT-CI score of 0, corresponding to a
low comorbidity risk, a scoring of 1 or 2 was seen for
nine patients and 10 patients scored 3 or higher. When
comparing the comorbidity index for nonresponders and
responders, we did not find any statistically significant
difference (P = 0.5256, Mann–Whitney U-test).
The effect of treatment on quality of life - responder
patients spend most of their time at home
Quality of life is usually reduced in AML patients at the
time of diagnosis but will later stabilize [25,26]. Several
instruments have been used for such analyses in random-
ized studies [25-27], but the aim of our nonrandomized
study was to investigate whether disease stabilization in
response to low-intensity treatment allowed the patients
to stay at home, and we therefore investigated this end-
point by analyzing days out of hospital. Time in hospital
was significantly shorter for our 11 responder patients
compared with the nonresponders (Mann–Whitney U-
test, P = 0.0038); the mean percentage of days in hospital
relative to total survival time being 24% for the responders
and 52% for the nonresponders. The median number of
days in hospital was 41 days (Table 5; range 12 to 93;
median survival 171 days) for the responders and 17
days (range 2 to 50; median survival 33 days) for the
nonresponders.
Treatment with valproic acid/ATRA/low-dose cytarabine
reduces the levels of circulating Treg cells but does not
affect Th17 levels
Rapid lymphoid reconstitution after AML therapy is as-
sociated with increased survival, an observation indicat-
ing that immunological events early after chemotherapy
are clinically important [21,28]. Increased levels of T
helper cells type 17 (Th17) and regulatory T cells (Treg)
have been found in untreated AML and increased Treglevels seem to be associated with an adverse prognosis
[29-31]. We therefore determined the levels of proin-
flammatory Th17 and Treg CD4+ T cells for an unse-
lected/consecutive subset of patients included in the
study. Treg levels were significantly increased in AML
patients before treatment (Mann- Whitney U-test, P =
0.003) compared with healthy controls, and these levels
were significantly reduced following treatment with val-
proic acid/ATRA/low-dose cytarabine (Figure 2; Wilcoxon
signed rank test, P = 0.0469). For the Th17 cells, we did
not observe any statistically significant differences be-
tween healthy controls, patient levels before treatment
or levels following treatment with valproic acid/ATRA/
cytarabine (data not shown).
Effects of valproic acid/ATRA/low-dose cytarabine on
levels of circulating reticulated platelets
Reticulated platelets represent the most recently released
platelets and thereby reflect the platelet production [32].
Increasing levels after AML chemotherapy seem to pre-
dict hematopoietic reconstitution [20,32,33]. We exam-
ined the levels of reticulated platelets in patients before
start of therapy (day 1), after one week of valproic acid
treatment (day 8), after one additional week of combined
treatment with valproic acid and ATRA (day 15), and fi-
nally after treatment with valproic acid, ATRA and 10
days of low-dose cytarabine (days 25 to 27). We detected
a significant increase in reticulated platelet counts dur-
ing the first 15 days of treatment (Wilcoxon’s signed
rank test, P = 0.0106), but a similar difference could not
be detected after 10 days of cytarabine treatment, and
there was no difference between patients with stable
Figure 2 The levels of circulating Treg cells in untreated acute
myeloid leukemia (AML) and the effect of all-trans retinoic acid
(ATRA), valproic acid and low-dose cytarabine on regulatory T
cells (Treg) cell levels. (Left) The levels of circulating Treg cells were
determined for a consecutive group of nine AML patients and these
levels were compared with a control group matched for age and
gender distribution. The mean level is indicated in the figure. (Right)
Treg levels were compared for seven patients before and following
treatment with valproic acid, ATRA and low-dose cytarabine.
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initial increase in reticulated platelets has previously
been described for AML patients treated with ATRA,
valproic acid and theophylline [15].
Heat shock proteins and cytokines
We have previously examined the serum levels of heat
shock protein (HSP) 70 and HSP90 as well as a wide
range of cytokines for an unselected/consecutive subset
of patients included in this study [34]. The cytokines in-
cluded (i) immunomodulatory cytokines (CD40-Ligand,
TNFα, IFNγ), (ii) interleukins (IL-1α, IL-1ß, IL-1ra, IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17), (iii)
chemokines (CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-
1ß, CCL5/Rantes, CCL11/Eotaxin, CXCL5/ENA-78,
CXCL8/IL-8, CXCL10/IP10, CXCL11/I-TAC) and (iv)
the growth factors granulocyte- and granulocyte-macro-
phage colony-stimulating factor (G-CSF and GM-CSF),
epithelial growth factor (EGF), hepatocyte growth factor
(HGF), basic fibroblast growth factor (bFGF), thrombo-
poietin (Tpo), vascular endothelial growth factor (VEGF)and leptin. These studies were described in a previous re-
port [34] and we now investigated whether cytokine levels
showed any association with response to therapy. How-
ever, only leptin showed a significant difference and was
increased in responding patients (Mann- Whitney U-test,
P = 0.0033) compared to nonresponders.
Discussion
The median age of AML patients at time of diagnosis is
65 to 70 years, and many of these patients do not receive
intensive chemotherapy due to a high risk of treatment-
related mortality [4,35-37]. Low-toxicity disease-stabilizing
therapy based on the use of ATRA and valproic acid has a
clinically relevant anti-leukemic effect for a subset of such
patients even though complete hematological remissions
are uncommon [8-15]. However, low-toxicity treatment
with cytotoxic drugs has not been an integrated feature in
any of these studies. In the present study we describe that
the combination of ATRA, valproic acid and low-dose
cytarabine is safe and results in disease stabilization and
possibly complete hematological remission (2 out of the
36 patients) for a relatively large subset of patients.
One previous study investigated the effect of valproic
acid plus low-dose cytarabine [16]. These authors also
included patients with MDS; they used higher cytarabine
doses that were administered more frequently and ATRA
was not included. Previous studies of low-dose cytarabine
have demonstrated that even this treatment can have a
treatment-related mortality [38]. However, our study of an
unselected patient population has demonstrated that this
low-toxicity regimen can give disease stabilization for a
subset of AML patients.
Response criteria for AML patients treated with inten-
sive chemotherapy [17], and for MDS patients receiving
disease-directed therapy [18,19], have been defined previ-
ously. There is no general agreement on how responses to
treatment should be classified in AML patients receiving
disease-stabilizing treatment. We used the MDS criteria
for response evaluation in our patients, and the blast cri-
teria for complete hematological remission are similar for
AML and MDS [17-19]. The MDS criteria for stable dis-
ease require improvement/stabilization of peripheral blood
cell counts for at least two months. The median survival
for older AML patients not receiving disease-directed
therapy is only two to three months [2,36,39], and
stabilization of the disease for more than two months is
therefore unexpected and should in our opinion be
regarded as a response to treatment.
Our patients showed a relatively low complete remis-
sion rate of 6%; this is considerably lower than the previ-
ous MRC study that showed a remission rate of 20%
after low-dose cytarabine [40]. However, the remission
rate for patients receiving low-dose cytarabine seems to
be dose-dependent: (i) the cytarabine dose in the MRC
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six weeks and the remission rate was then 20%; (ii)
Kantarjian et al. [41] used cytarabine 20 mg/m2 once
daily for 10 days at four-week intervals and had a remis-
sion rate of 7.9%; whereas (iii) we used an even lower
dose of 10 mg/m2 for 10 days at 12- week intervals, but
despite this our remission rate of 6% is comparable to
Kantarjian et al. even though we included patients with
AML relapse. Our present observations are also consistent
with earlier AML studies of low-dose cytarabine [38].
One possible explanation for the difference in survival
between our responder and nonresponder patients could
be that our treatment identified a patient subset with a
better prognosis. Even though a randomized clinical study
is necessary to give a final answer to this question, patient
selection alone seems less likely because: (i) we observed
two complete remissions and spontaneous remission is
very uncommon in AML; (ii) spontaneous improvement
in peripheral blood cell counts is also uncommon; and (iii)
many of our responders lived considerably longer (median
survival of the responders > five months) than the patients
in an unselected control group receiving supportive treat-
ment according to the same institutional guidelines. How-
ever, this last comparison with historical controls should
be interpreted with great care. Finally, we would empha-
size that increased platelet counts and neutrophil counts
> 0.5 × 109/L in the responder patients (Table 4) are clin-
ically important and decreases the risk of severe complica-
tions in these patients.
Our study had a relatively high first four-week mortal-
ity rate of 30%. Although a similar mortality has also
been described in other studies of older AML patients
[42], it is usually 5 to 15% in recent studies of older
AML patients [41,43-45]. Menzin et al. [39] investigated
an unselected population of 2,657 patients with newly
diagnosed AML above 65 years of age; their median age
was 77 years and the median survival for all patients was
only two months even though 790 patients received
some kind of antileukemic chemotherapy. For patients
above 85 years of age, the median survival was only one
month and for patients between 75 and 85 years it was
two months [39]. This association between age and sur-
vival has been confirmed by others [2]. The patient
population in Menzin’s study [39] is very similar to the
patients included in our present study except that we
also included high-risk patients with AML relapse. Thus,
our relatively high early mortality can be explained by a
combined effect: (i) a higher age of our patients (median
77 years, range 48 to 90 years) than for many other stud-
ies, and for such an unselected older population a very
short median survival is expected [39]; (ii) many of our
patients had a higher performance status than patients
included in other studies and this is also associated with
short survival [2,41,43-45]; (iii) our inclusion of AMLrelapse patients (19% of our patients) will increase the
number of patients with resistant disease and thereby
early progression; and (iv) there is often a delay of one to
three weeks before an effect of HDAC inhibition + ATRA
can be detected (Table 4). Thus, in this context, our early
four-week mortality of 30% is not unexpected. In our
study, cytarabine was started after 14 days of treatment
with valproic acid/ATRA; our intention was to reduce the
problems with cytarabine-induced cytopenia by inducing
increased normal cell counts prior to this therapy. How-
ever, even though ATRA plus HDAC inhibition can re-
verse leukocytosis, our high early mortality may suggest
that chemotherapy should start earlier when combined
with ATRA/valproic acid in older unfit patients.
In a previous clinical study we described an effect of
ATRA, valproic acid and theophylline on peripheral
blood blast counts for a subset of AML patients [15,46].
Other studies have also described comparable results
only after treatment with ATRA plus valproic acid
[8-14], and for this reason we used only these two drugs
in our present study and theophylline was left out. Fur-
thermore, we showed a clinical effect when using ATRA
only for two-week cycles [15]; other AML studies used
ATRA as continuous therapy but we used the intermittent
treatment also in our present study. This intermittent
strategy of ATRA treatment is also used in AML-M3
maintenance therapy [47,48]. Finally, we added chemo-
therapy in our present study to increase the anti-leukemic
effect and to increase the possibility of achieving better
early control of hyperleukocytosis. We decided to use low-
dose cytarabine because in our opinion this was the best
documented low-toxicity treatment in human AML, and
we also used the lowest dose previously examined in clin-
ical trials because even low-dose cytarabine may cause
treatment-related mortality (reviewed in [38]). To reduce
the risk of chemotherapy-induced thrombocytopenia, we
started with cytarabine after 14 days of treatment with
ATRA plus valproic acid; our previous study showed that
even for patients responding to this treatment with a
platelet increase, there can be an initial decrease in reticu-
lated and total platelet counts [15] and, therefore, if pos-
sible, we wanted to reduce the risk of producing a dual
platelet-reducing effect.
Several HDAC inhibitors have now been developed
and tried in clinical studies [49]. Vorinostat has been
tried in phase I and phase II AML studies; some of these
studies have combined vorinostat with demethylating
agents or conventional chemotherapy, but the results for
vorinostat monotherapy in human AML are comparable
to the results for valproic acid treatment [5,50-53]. The
same is true for MGCD0103 (mocetinostat), entinostat,
panobinostat and romidepsin; to the best of our know-
ledge no available studies have documented that these
agents are superior to valproic acid. Thus, we used
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because it is a safe alternative, analysis of serum levels is
easily available and it seems as equally effective as other
HDAC inhibitors.
During the study period, a majority of AML patients
admitted to our institution and found to be unfit for in-
tensive chemotherapy were included in our study, and
several of these patients had high-risk disease (for ex-
ample, high-risk cytogenetics, relapsed AML, secondary
AML). Some of our stable disease/responder patients
also had high-risk characteristics. Our study thus in-
cluded an unselected group of patients, and responses
could be seen even in high-risk patients according to
conventional risk stratification [1,54].
Several previous studies of ATRA plus valproic acid-
based disease-stabilizing treatments in AML have been
published; these studies included a total of 244 patients
and only three complete hematological remissions were
then observed. Remission was thus very uncommon for
these patients [9,10,12-14]. In contrast, we observed two
patients with complete remission in our present study,
an observation suggesting that the combination with
cytotoxic drugs increases the anti-leukemic effects in
ATRA plus valproic acid and makes complete remissions
more common. Our present study demonstrates that
low-dose cytarabine is effective and feasible, but in our
opinion it is difficult to judge whether it is superior to
hydroxyurea or 6-mercaptopurine. The anti-leukemic ef-
fect of low-dose cytarabine has been documented in sev-
eral clinical studies [38] including a randomized study
comparing this treatment with hydroxyurea [40]. How-
ever, the patients in this MRC study received higher
doses of cytarabine than our patients (20 mg/m2 twice
daily versus 10 mg/m2 once daily for 10 days) and the
treatment was also given more frequently (every fourth
to sixth week versus every third month). In addition to
this, the MRC study had a majority of de novo AML pa-
tients (129/217 or 59%), whereas in our material only
28% had de novo disease. Our patients were also slightly
older (median age 77 versus 74) and they had a worse
WHO performance status (42% versus 30% WHO score
3 to 4). On the other hand, our present results show that
oral hydroxyurea or 6-mercaptopurine could be effective
for patients showing early progression after low-dose
cytarabine, and the two oral alternatives are also easier
to handle for the patients.
The valproic acid levels varied between patients but
we could not observe any difference in the serum
levels between nonresponders and responder patients.
These observations strongly suggest that the valproic
acid serum level is not decisive for the treatment re-
sponse; a more likely explanation is that the respon-
siveness depends on biological characteristics of the
patients.The aim of our study was to achieve disease-stabilization/
improvement so that the patients could stay at home dur-
ing treatment. Our responder patients had a prolonged
survival compared to the nonresponders, and most of this
time was spent at home. Previous studies have shown that
the quality of life is related to response to therapy [55]. In
this context it seems likely that the treatment-induced
AML stabilization, or even induction of remission, in our
responder patients improved their quality of life.
During treatment, we detected altered levels of normal
peripheral blood cells. Firstly, increased levels of reticu-
lated platelets were detected during the initial treatment
with valproic acid plus ATRA alone, and we observed a
similar increase in our previous study during treatment
with ATRA plus valproic acid plus theophylline [15].
Taken together, these observations suggest that theo-
phylline is not required for these responses. Further-
more, we observed unaltered levels of pro-inflammatory
Th17 cells but decreased levels of immunosuppressive
Treg cells during treatment. High Treg levels are associ-
ated with an adverse prognosis in AML patients receiv-
ing intensive chemotherapy [29,31], but our present
study is too small to allow any conclusion about a pos-
sible prognostic impact of Treg levels in patients receiv-
ing disease-stabilizing treatment. It is not possible to
judge from our present results whether the effects of re-
ticulated platelets, Th17 or Treg cells are directly caused
by the treatment or whether they are indirect effects
caused by the improved disease control.
The most important observations/conclusions from
previous studies of valproic acid + ATRA treatment are
summarized in Table 6 [8-11,13-16,56-58], and more de-
tailed information is given in our recent review of valproic
acid in the treatment of human AML [59]. Concerning
valproic acid + ATRA alone, we conclude that this is a
safe treatment that induces hematological improvement
for 20 to 40% of patients, but complete remissions are
rare. This response rate is seen even for unselected and
mainly older patients, including patients with high-risk
disease. If valproic acid is combined with more intensive
chemotherapy (cytarabine or 5-azacitidine) the remission
rate increases, even though one exceptional and relatively
small study using low-dose cytarabine, together with val-
proic acid and ATRA, showed no remissions among 19
patients [56]. However, it can be questioned whether the
remission rate should be the only or the best marker of a
clinically important effect for patients receiving disease-
stabilizing antileukemic therapy [60]. This is supported by
a recently published randomized study of clofarabine ver-
sus low-dose cytarabine where clofarabine increased the
remission rate but did not improve overall survival [61].
In contrast, when 5-azacitidine treatment was compared
with conventional care regimen (doctors’ choice of pallia-
tive care alone, low-dose cytarabine or intensive chemo-
Table 6 Clinical studies of valproic acid in the treatment of human acute myeloid leukemia (AML); a summary of the
previous clinical results from studies of valproic alone, valproic acid + all-trans retinoic acid (ATRA) used alone and in
combination with other pharmacological agents
Treatment Studies Patient
number
Most important observations
Valproic acid monotherapy Kuendgen [12] N = 31 This study included 31 patients receiving valproic acid alone and 40 patients
receiving valproic acid plus continuous ATRA. Hematological improvement
according to the myelodysplastic syndrome (MDS) criteria was also seen with
valproic acid alone for a minor subset of patients.
Valproic acid + ATRA Kuendgen [12] N = 40 Based on the overall results the following conclusions can be made:
Bellos [8] N = 22 • This is a nontoxic treatment, the most frequent side effects being dose-
dependent and thereby reversible fatigue and gastrointestinal discomfort.
ATRA syndrome is very uncommon and has only been reported in one of
these studies.
Bug [9]
N = 26
Cimino [10] N = 8 • The two drugs can be combined with initial low-toxicity chemotherapy to
control hyperleukocytosis (hydroxyurea, cytarabine, 6-mercaptopurin).
Raffoux [14] N = 11
Pilatrino [13] N = 20 • Complete remissions are uncommon, probably < 2 to 3%.
• Hematological improvement as defined by the MDS criteria is seen for 20
to 40% of patients; platelet responses seem most common but erythroid and
neutrophil responses may also be seen.
• Responses can be seen even with valproic acid levels lower than the
therapeutic serum level commonly used for this drug.
• ATRA is usually used as 45 mg/m2/day; continuous ATRA therapy has been
used in most studies but intermittent treatment for 14 days at intervals up to 12
weeks may also be used.
• It is uncommon for responses to last for more than one year.
• Median age in most studies is 65 to 75 years; the treatment has been used
for patients up to 90 years of age.
Valproic acid + ATRA +
theophylline
Ryningen [15] N = 24 Continuous valproic acid + theophylline was combined with intermittent
ATRA 22.5 mg/m2 twice daily for 15 days with 12 weeks intervals; 18% of
patients had hematological improvement according to the MDS criteria, 2
patients developed atrial fibrillation and the most common side effects were
dose-dependent nausea and fatigue.
Valproic acid +ATRA +
low-dose cytarabine
Lane [56] N = 19 Lane: no complete or partial remissionsCorsetti: the study included 25 AML
and 6 high-risk MDS patients; 8 patients obtained a complete remission and
3 additional patients obtained hematological improvement.Fredly: two
complete remissions and 9 patients with hematological improvement.
Corsetti [16] N = 31
Fredly (present
study)
N = 36
Valproic acid + ATRA +
decitabine
Raffoux [57] N = 65 Raffoux: six cycles were given; 34 patients were then alive and among these
38% achieved complete remission, 6% partial remission and 41% stable
disease. There were 76 events of infections.Soriano [58] N = 53
Soriano: 42% overall response rate with 22% complete remissions. The most
important nonhematological toxicity was 13 events of grade III/IV
neurotoxicity.
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5-azacitidine significantly increased the overall survival
even for high-risk patients [62]. It has therefore been sug-
gested that strategies for improving survival with epigen-
etic therapy, without improving the remission rate, may
be particularly suitable for older AML patients [60].
An alternative strategy for epigenetic targeting is
decitabine, another inhibitor of DNA methylation. This
drug showed a complete remission rate of 24% when
tested in a phase II study including only older patients
(median age 74 years) [43]. A high complete remission
rate was also seen in another study [63]. Decitabine haseven been tried as prolonged consolidation therapy in
older people [45]. Finally, an unplanned final analysis of
a randomized clinical trial showed that decitabine
caused a significantly increased complete remission rate,
but no difference in overall survival, compared with pa-
tients’ choice after physicians’ advice (mainly low-dose
cytarabine) [41]. There is therefore no general agreement
on whether decitabine should be recommended for the
treatment of older AML patients [64]. Rather, the obser-
vation of a high remission rate without increased overall
survival supports the hypothesis by Amadori et al. [60]
that remission rate alone may not be an optimal pre-
Fredly et al. Clinical Epigenetics 2013, 5:13 Page 13 of 15
http://www.clinicalepigeneticsjournal.com/content/5/1/13dictor of survival after epigenetic therapy in older AML
patients.
Conclusion
The combination of valproic acid, ATRA and low-dose
cytarabine is a safe alternative for AML patients unfit
for intensive chemotherapy, but only a minority of pa-
tients respond to the treatment and relatively few pa-
tients achieved complete remission. In contrast to the
investigators of a previous smaller study [56] we there-
fore conclude that this low-toxicity therapeutic strategy
should be further investigated in AML therapy, and our
conclusion is also supported by a third and relatively
large study that observed a relatively high complete re-
mission rate for patients receiving this treatment [16].
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